Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 148, Issue -, Pages 88-106Publisher
ELSEVIER
DOI: 10.1016/j.ejpb.2019.10.013
Keywords
Cancer targeting; Osteosarcoma; Doxorubicin; Micelleplexes; Nucleic acid delivery; Active targeting
Categories
Funding
- Portuguese Foundation for Science and Technology (FCT) [FCT PTDC/BTM-MAT/30255/2017, FCT PTDC/BTM-MAT/30255/2017 (POCI-01-0145-FEDER-030255)]
- European Community Fund (FEDER) through the COMPETE2020 program
- National Funds (FCT/MEC, Fundacao para a Ciencia e Tecnologia/Ministerio da EducactIo e Ciencia) [UID/QUI/50006/2013]
- European Union (FEDER under the Partnership Agreement PT2020)
- MINECO [SAF2017-83118-R]
- Agencia Estatal de Investigacion (AEI) Spain
- Xunta de Galicia (Grupo de Referencia Competitiva) [ED431C 2016/008]
- FEDER (Spain)
Ask authors/readers for more resources
Osteosarcoma(OS) represents the main cancer affecting bone tissue, and one of the most frequent in children. In this review we discuss the major pathological hallmarks of this pathology, its current therapeutics, new active biomolecules, as well as the nanotechnology outbreak applied to the development of innovative strategies for selective OS targeting. Small RNA molecules play a role as key-regulator molecules capable of orchestrate different responses in what concerns cancer initiation, proliferation, migration and invasiveness. Frequently associated with lung metastasis, new strategies are urgent to upgrade the therapeutic outcomes and the life-expectancy prospects. Hence, the prominent rise of micelleplexes as multifaceted and efficient structures for nucleic acid delivery and selective drug targeting is revisited here with special emphasis on ligand-mediated active targeting. Future landmarks toward the development of novel nanostrategies for both OS diagnosis and OS therapy improvements are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available